Research
Hormonal
Glucagon-like peptide 1 receptor agonists hold great promise to reverse some cancer risk in people living with obesity.
GLP-1 receptor agonists may be considered in obesity management to potentially reduce cancer risk.
StrongSupportsmedium confidence
Glucagon-like peptide 1 receptor agonists hold great promise to reverse some cancer risk in people living with obesity.
Why this rating
Emerging clinical trials support the claim.
Source
Will GLP-1 Agonists Weaken the Links between Obesity and Cancer?
Donal J. Brennan et al. · Cancer Discovery · 2025
reviewCited 1×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →